Search research articles
Contact Us
Filters
Showing results (101-110 of 215) with videos related to
Page
of 22
Sort By:
Medical Acupuncture
|
April 25, 2014
The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial
Weidong Lu, Ursula A Matulonis, Julie E Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
Ursula A Matulonis, Neil S Horowitz, Susana M Campos, et al.
Gynecologic Oncology Reports
|
February 22, 2020
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Elizabeth K Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer
Michael J Callahan, Zoltan Nagymanyoki, Tomas Bonome, et al.
Gynecologic Oncology
|
September 19, 2003
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors
Susanna M Campos, Ursula A Matulonis, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2018
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
Ursula A Matulonis, Michael J Birrer, David M O'Malley, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2021
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Joyce F Liu, Niya Xiong, Susana M Campos, et al.
Cancer Research Communications
|
February 11, 2025
Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma
Zelei Yang, Saie Mogre, Hyeji Jun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor
Angelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
Page
of 22
Search research articles
Search
Showing results (101-110 of 215) with videos related to
Sort By:
Page
of 22
Medical Acupuncture
|
April 25, 2014
The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial
Weidong Lu, Ursula A Matulonis, Julie E Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
Ursula A Matulonis, Neil S Horowitz, Susana M Campos, et al.
Gynecologic Oncology Reports
|
February 22, 2020
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Elizabeth K Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer
Michael J Callahan, Zoltan Nagymanyoki, Tomas Bonome, et al.
Gynecologic Oncology
|
September 19, 2003
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors
Susanna M Campos, Ursula A Matulonis, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2018
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
Ursula A Matulonis, Michael J Birrer, David M O'Malley, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2021
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Joyce F Liu, Niya Xiong, Susana M Campos, et al.
Cancer Research Communications
|
February 11, 2025
Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma
Zelei Yang, Saie Mogre, Hyeji Jun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor
Angelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
Page
of 22